EGFR and COVID-19: While lapatinib has not been studied for the treatment of viral infections to date, ibrutinib, a BTK inhibitor with potent pan-ErbB activity (21) that we show suppresses SARS-CoV-2 and VEEV infections, has shown protection from progression to severe COVID-19, albeit in a small number of patients (50).